UBE2C and cholangiocarcinoma: Our cross-analysis using published transcriptome data sets and our clinical cohort demonstrated that UBE2C was significantly highly expressed in cholangiocarcinoma tumor tissues, and high expression of UBE2C was significantly associated with worse overall survival, disease-specific survival, local recurrence-free survival, and metastasis-free survival in patients with cholangiocarcinoma.